ELDN
Eledon Pharmaceuticals, Inc. Common Stock
stockNASDAQ
eledon pharmaceuticals, inc. is a clinical stage biotechnology company using its expertise in targeting the cd40l pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. our lead program, at-1501, is a potential best-in-class humanized igg1 anti-cd40l antibody with high affinity for cd40l, a well-validated biological target with broad therapeutic potential. the cd40/cd40l pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.64 | 2026-09-28 | -5.68% | 4.222 |
| 1M | 3.02 | 2026-09-04 | -17.55% | 1.899 |
| 3M | 3.97 | 2026-07-06 | -37.28% | 0.794 |
| 6M | 3.09 | 2026-04-06 | -19.42% | 1.086 |
| 1Y | 2.84 | 2025-10-03 | -12.32% | 1.841 |
| 2Y | 2.62 | 2024-10-04 | -4.96% | — |
| 5Y | 5.75 | 2021-10-04 | -56.70% | 0.548 |
Eledon Pharmaceuticals, Inc. Common Stock (NASDAQ:ELDN) stock price today is $2.49, and today's volume is 973,163. ELDN is up 2.259% today. The 30 day average volume is 943,727. ELDN market cap is $202.34M with 81.26M shares outstanding.